NCT05277636 (R-S-MDMA) is a Phase 1 clinical trial of 3,4-methylenedioxymethamphetamine in Healthy, sponsored by University Hospital, Basel, Switzerland.

Who is sponsoring NCT05277636?

NCT05277636 is sponsored by University Hospital, Basel, Switzerland.

What drugs are being tested in NCT05277636?

Interventions in NCT05277636: 3,4-methylenedioxymethamphetamine, S-3,4-methylenedioxymethamphetamine, R-3,4-methylenedioxymethamphetamine (125 mg), R-3,4-methylenedioxymethamphetamine (250 mg), Placebo.

Is NCT05277636 still recruiting?

NCT05277636 is currently completed. Last updated 17 January 2024.

Last reviewed 2024-01-17 · How we verify

NCT05277636: R-S-MDMA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute Effects of R- and S-MDMA in Healthy Subjects

Completed Phase 1 Last updated 17 January 2024

What this trial tests

Phase 1 trial testing 3,4-methylenedioxymethamphetamine in Healthy in 24 participants. Completed in 13 January 2024.

Timeline

1 October 2022

Primary endpoint
13 January 2024

13 January 2024

Quick facts

Lead sponsor	University Hospital, Basel, Switzerland
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	basic science
Enrollment	24
Start date	1 October 2022
Primary completion	13 January 2024
Estimated completion	13 January 2024
Sites	1 location across Switzerland

Drugs / interventions tested

3,4-methylenedioxymethamphetamine
S-3,4-methylenedioxymethamphetamine — full drug profile →
R-3,4-methylenedioxymethamphetamine (125 mg) — full drug profile →
R-3,4-methylenedioxymethamphetamine (250 mg) — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

University Hospital, Basel, Switzerland

Who can join

Adults 18 to 65, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Racemic ±3,4-methylenedioxymethamphetamine (MDMA) is a psychoactive substance and prototypical empathogen acutely inducing feelings of heightened mood, empathy, trust and closeness to others. These acute subjective effects of MDMA may be helpful to assist psychotherapy and MDMA is currently investigated in phase 3 trials as a possible treatment in post-traumatic stress disorder.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants.
Straumann I, Avedisian I, Klaiber A, Varghese N, et al · · 2024 · cited 12× · PMID 39179638 · DOI 10.1038/s41386-024-01972-6

Verify or expand the search:

Other trials of 3,4-methylenedioxymethamphetamine

Trials testing the same drug.

NCT05523401 — Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects · Phase 1 · completed
NCT04847206 — Effects of MDMA-like Substances in Healthy Subjects · Phase 1 · completed
NCT05488171 — Abuse Potential and Human Pharmacology of Methylone · Phase 1 · unknown
NCT04264026 — MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD · Phase 2 · completed
NCT04516902 — Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects · Phase 1 · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05277636 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
Last refreshed: 17 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05277636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing